Welcome to Stock Trading Signals

Daily Top Stocks Pick Alert

Hottest Stocks in 2015- ANAC- ZIOP -ADXS- EXEL
Hottest Penny Stocks in 2015 - CTRV -HLTH-FRO
Stocks Pick in 2015 - AAPL - BAC - ANR - X
Hottest Stocks in 2014- AVNR- AGIO -ACH- VDSI
Hottest Penny Stocks in 2014 - JOB -PLUG-QTM
My Daily Trading Activities - Membership Link

Tuesday, June 26, 2012

Top Gainers & Losers in After-hours 6/26/12 June 26, 2012

During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up  with news.If you are looking to day trade  also check out my Top  2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have  technical analysis different stocks-Right Here. Market Technical analysis Right Here
 
Quick Look Market Closing Price:   

At the close: Dow +0.45% to 12560. S&P +0.65% to 1322. Nasdaq +0.63% to 2854.
Treasurys: 30-year -0.29%. 10-yr -0.14%. 5-yr -0.06%.
Commodities: Crude +0.15% to $79.33. Gold -0.89% to $1574.25.
Currencies: Euro -0.04% vs. dollar. Yen -0.21%. Pound -0.43%.


After Hours News: 
AeroVironment (AVAV): FQ4 misses on revenue but beats on a per share basis as the company posted higher unmanned aircraft sales, though margins weakened. The company also issued an upbeat outlook for the new fiscal year, now expecting FY earnings of $1.41 to $1.51 per share on revenue of $348M to $370M. Street expectations are for an EPS of $1.44 on $349M in revenue. Shares +8.8% AH

Sealy Corporation (ZZ): FQ2 EPS of $0.03 beats by $0.02. Revenue of $312M (-2.9% Y/Y) in-line

H&R Block (HRB): FQ4 misses on a per share basis while coming in line with revenue expectations. Total revenue declined by 2.2% Y/Y however, due in large part to a previously announced strategic realignment and litigation expenses. Client share grew in both the assisted and digital categories, reaching a record 25.6M clients for the year. Shares +2.3% AH

Amicus Therapeutics (ERT) says it's achieved positive preliminary results from its ongoing phase 2 open-label drug-drug interaction study to evaluate the safety and effects of AT2220, co-administered with enzyme replacement therapy for Pompe disease. Shares -1.5% AH.

For the latest updates on the stock market, visit, 
http://daytradingstock-blog.blogspot.com/